Catalent (NYSE:CTLT) quickly rose 1% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings ...

Robert W. Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock ...

Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $61.84 which represents a slight increase of $0.14 or 0.23% from the prior close of $61.7. The stock opened at $61.75 and touched a low ...

Catalent, Inc. (“Catalent”) and Novo Holdings A/S (“Novo Holdings”) jointly announced today the unconditional approval granted by the European Commission (EC) for the pending acquisition transaction ...

Catalent (CTLT) shares rise 1% as Novo Holdings explores contract extensions with concerned drugmakers post $16.5 billion ...

CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading. The company provides filling and packaging services for syringes ...

Highlights,State Street Corp increased its stake in Catalent by 1.5% in Q3.,Catalent reported a slight miss on earnings in ...

Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holding ...

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.